Pharmacologic treatments for covid-19 patients

Nafamostat vs Standard care

This comparison will not be updated. Last search date 28 Feb, 2022.


Hospitalized patients

Forest plots
(last update: 2022-05-16)

Summary of findings
(last update: 2022-05-18)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=534

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
NCT04623021
Zhuravel SV, EClinicalMedicine, 2021
Full text
00449-1/fulltext Commentary
Mixed

Nafamostat

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 13 centers in Russia N=104
Some concerns
Details

Full description

NCT04473053; ISRCTN14212905; EudraCT 2020-002230-3
DEFINE
Quinn TM, EBioMedicine, 2022
Full text
Full text
Commentary
Commentary
Commentary
Mixed

Nafamostat

Standard care

RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centres in the UK N=44
Some concerns
Details

Full description